Makhachkala

Researchers are conducting a large, non-interventional observational study to better understand adults with uncontrolled asthma across Russia. This study aims to gather detailed information on the demographic and clinical characteristics of these patients, the treatments they receive, and how their condition is managed in routine clinical practice. The study focuses on patients not treated with biologics and covers a diverse population from about 50 regions in Russia, reflecting differences in ethnicity, climate, and economic status. The study will include 9,000 adult patients with uncontrolled mild to moderate asthma who are receiving standard care. Data will be collected during 2-3 visits that follow routine clinical practice schedules. At the first visit, information from the previous 52 weeks will be gathered from medical records and patient interviews. The second visit will take place about 12 weeks later to collect follow-up data on treatment changes and clinical outcomes. For a subgroup of 500 patients using a fixed-dose combination of budesonide/salbutamol at the second visit, an additional third visit will occur 12 weeks later to further monitor treatment and outcomes. Participants will be monitored through medical record reviews and interviews during these visits. Researchers will assess baseline characteristics such as blood eosinophil counts, sputum eosinophils, and total IgE levels, along with treatment profiles and clinical outcomes. The study does not involve any experimental interventions beyond standard care and aims to provide comprehensive real-world data on uncontrolled asthma management in Russia. The total study duration for participants includes up to 24 weeks of follow-up for some patients.

Researchers are conducting a multicenter observational study in the Russian Federation to understand treatment approaches and the prevalence of HER2 positive status in different stages of bladder cancer, as well as PD-L1 positive status in metastatic bladder cancer. This study includes approximately 600 adult patients diagnosed with urothelial bladder cancer at various stages: high-risk non-muscle invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), and metastatic bladder cancer (mBC). The study does not involve any intervention but collects primary and secondary clinical data for descriptive and epidemiologic analysis. Patients will be grouped into three cohorts based on their bladder cancer stage at enrollment. Data collection involves one routine clinical visit where demographic information, clinical characteristics, medical history, and treatment approaches are recorded. Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples collected during routine care will be sent to a central laboratory for immunohistochemistry testing. The study plans to enroll patients over approximately 18 months across about 30 oncology centers in Russia. During the single study visit, investigators will enter patients' medical data into electronic case report forms from medical records. No follow-up visits are planned. The study will measure outcomes such as proportions of patients receiving various treatments over 24 months, number and timing of cancer relapses, progression to metastatic disease, and treatment responses. Safety monitoring or additional interventions are not part of this observational study.